These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Systematic profiling of SARS-CoV-2-specific IgG epitopes at amino acid resolution. Qi H; Ma ML; Jiang HW; Ling JY; Chen LY; Zhang HN; Lai DY; Li Y; Guo ZW; Hu CS; Guo SJ; Meng QF; Ren Y; Yang X; Wang W; Zhou J; Zhao XD; Li H; Tao SC Cell Mol Immunol; 2021 Apr; 18(4):1067-1069. PubMed ID: 33664486 [No Abstract] [Full Text] [Related]
4. New antibodies that the coronavirus can't elude. Service RF Science; 2023 May; 380(6647):779-780. PubMed ID: 37228211 [TBL] [Abstract][Full Text] [Related]
5. Characterization of SARS-CoV-2-specific antibodies in COVID-19 patients reveals highly potent neutralizing IgA. Zeng W; Ma H; Ding C; Yang Y; Sun Y; Huang X; He W; Xiang Y; Gao Y; Jin T Signal Transduct Target Ther; 2021 Jan; 6(1):35. PubMed ID: 33514692 [No Abstract] [Full Text] [Related]
6. Is preexisting immunity to seasonal coronaviruses limited to cross-reactivity with SARS-CoV-2? A seroprevalence cross-sectional study in north-eastern France. Zedan HT; Nasrallah GK EBioMedicine; 2021 Sep; 71():103580. PubMed ID: 34525435 [No Abstract] [Full Text] [Related]
7. The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2. Li C; Tian X; Jia X; Wan J; Lu L; Jiang S; Lan F; Lu Y; Wu Y; Ying T Signal Transduct Target Ther; 2021 Mar; 6(1):132. PubMed ID: 33758169 [No Abstract] [Full Text] [Related]
8. Structure-based development of human antibody cocktails against SARS-CoV-2. Wang N; Sun Y; Feng R; Wang Y; Guo Y; Zhang L; Deng YQ; Wang L; Cui Z; Cao L; Zhang YJ; Li W; Zhu FC; Qin CF; Wang X Cell Res; 2021 Jan; 31(1):101-103. PubMed ID: 33262454 [No Abstract] [Full Text] [Related]
10. Stereotypic neutralizing V Kim SI; Noh J; Kim S; Choi Y; Yoo DK; Lee Y; Lee H; Jung J; Kang CK; Song KH; Choe PG; Kim HB; Kim ES; Kim NJ; Seong MW; Park WB; Oh MD; Kwon S; Chung J Sci Transl Med; 2021 Jan; 13(578):. PubMed ID: 33397677 [TBL] [Abstract][Full Text] [Related]
11. [Not Available]. Béguelin A Rev Med Suisse; 2021 Jan; 17(723):234. PubMed ID: 33507668 [No Abstract] [Full Text] [Related]
12. Tackling COVID19 by Exploiting Pre-existing Cross-Reacting Spike-Specific Immunity. Zeng Q; Huang G; Li YZ; Xu Y Mol Ther; 2020 Nov; 28(11):2314-2315. PubMed ID: 33038327 [No Abstract] [Full Text] [Related]
13. SARS-CoV-2 spike therapeutic antibodies in the age of variants. Baum A; Kyratsous CA J Exp Med; 2021 May; 218(5):. PubMed ID: 33871567 [TBL] [Abstract][Full Text] [Related]
14. Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases. Vojdani A; Vojdani E; Kharrazian D Front Immunol; 2020; 11():617089. PubMed ID: 33584709 [TBL] [Abstract][Full Text] [Related]
16. Überantibodies From Recovered COVID-19 Patients Could Spur New Therapeutics and Vaccines. Abbasi J JAMA; 2021 Aug; 326(7):589-590. PubMed ID: 34319350 [No Abstract] [Full Text] [Related]
17. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern. Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR Front Immunol; 2021; 12():691715. PubMed ID: 34149735 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein. Tani H; Kimura M; Tan L; Yoshida Y; Ozawa T; Kishi H; Fukushi S; Saijo M; Sano K; Suzuki T; Kawasuji H; Ueno A; Miyajima Y; Fukui Y; Sakamaki I; Yamamoto Y; Morinaga Y Virol J; 2021 Jan; 18(1):16. PubMed ID: 33435994 [TBL] [Abstract][Full Text] [Related]
19. Production and application of polyclonal antibodies against SARS-CoV-2 viral spike protein. Development to rapid, highly sensitive diagnosis kit for early Corona viral detection among the population. Kavithaa K; Paulpandi M; Balachandar V; Ramesh M; Narayanasamy A Eur Rev Med Pharmacol Sci; 2020 Oct; 24(19):10219-10221. PubMed ID: 33090431 [TBL] [Abstract][Full Text] [Related]
20. IL-33 expression in response to SARS-CoV-2 correlates with seropositivity in COVID-19 convalescent individuals. Stanczak MA; Sanin DE; Apostolova P; Nerz G; Lampaki D; Hofmann M; Steinmann D; Krohn-Grimberghe M; Thimme R; Mittler G; Waller CF; Pearce EJ; Pearce EL Nat Commun; 2021 Apr; 12(1):2133. PubMed ID: 33837219 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]